ment Scheme in the various units of FCI and HFC are given below:—

Units/Division/Office	Number of employees who have taken voluntary retirement
1. Fertilizer Corporation of India Limited (FCI)	
(i) Sindri Unit	93
(ii) Ramagundam Unit	25
(iii) Talcher Unit	23
(iv) Gorakhpur Unit	133
(v) Marketing Division	18
(vi) Korba Division	7
(vii) Jodhpur	19
(viii) Central Office	66
TOTAL	384
2. Hindustan Fertilizer Corporation Limited (HFC)	
(i) Barauni Unit	129
(ii) Durgapur Unit	128
(iii) Namrup Unit	179
(iv) Haldia Division	145
(v) Marketing Division	133
(vi) Fertilizer Promotion and Agricultural Research Division	244
(vii) Calcutta Purchase Office	27
(viii) Corporate Office	39
TOTAL	1024

Study for Drug Industry

3775. SHRI RAJNI RANJAN SAHU : Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1337 given in the Rajya Sabha on the 5th December, 1991 and state:

(a) whether it is a fact that after 1970-71 no study of the break-even mark-up has been carried out by Government;

(b) why such a study is not being got conducted so as to know the real position of the drug industry;

(c) whether it is a fact that sandwitched between the issue of mark-up and trade commission, Government are ignoring the interests of common man; and

(d) what steps Government propose to take in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (d) Mark-up is provided to cover post manufacturing expenses over and above the ex-factory cost of production of a formulation, incurred by the manufacturer including trade commission and his profit margin. In determination of reasonable level of mark-up the situation prevailing in the industry and pharmaceutical market are taken into account while formulating the pricing policy from time to time. This is done with the objective of ensuring availability to consumers at reasonable prices and at the same time not making manufacture of medicines an unattractive proposition.

Permitting equity to foreign pharmaceutical companies

3776. SHRI SHIV PRATAP MISHRA: Will the PRIME MINISTER be pleased to state:

(a) whether Government propose to permit 51 per cent equity to foreign pharmaceutical companies ; and

(b) if so, the details thereof ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) and (b) The Drug Policy does not prescribe any limits on the

equity permissible to foreign pharmaceutical companies. However, manufacturing activities of FERA companies are limited to 66 bulk drugs listed in the statement and formulations based thereon.

Statement

1. Rifampicin
2. Verapamil
3. Cephalexin
4. Pantothenate
5. Bacitracin
6. Neomycin
7. Cephaloridine
8. Alkaloids of Ergot
9. Thiopentone
10. Propoxyphenazone
11. Pyrantal Pamoate
12. Norethisterone
13. Oxethazine
14. Pentazocin
15. Norgestral
16. Dipyridemol
17. Tolnaftate
18. Triprolidine
19. Naproxen
20. Nalidixic Acid
21. Chlorpromazine
22. Chlorpheniramine
23. Betamethazone
24. Dexamethazone
25. Chloramphenicol
26. Vitamin A
27. Digoxin
28. Dapsone
29. Allopurinol
30. Vitamin B 12
31. Prednizoione
32. Baralgan Ketone
33. Isulin
34. Primaquine
35. Amodiaquine
36. Succinyl Cholinechloride
37. Clofazamine
38. Thiabendazole
39. Tetramisole
40. Framycetin
41. Cyclophosphamide
42. Mepacrine
43. Triamcinolone
44. Phenuylephrine
45. Oxytecin
46. Vitamin P (Rutin)
47. Prenylamine Lacate
48. Thioridazine
49. Phenolthi zine
50. Penicillins
51. Mianserin Hydrochloride
52. Aminoglutethimid
53. Cinnarizine
54. Becampicillin
55. Captopril
56. Prazinuantel
57. Tobramycin
58. Timolol
59. Cazaoline Sodium
60. Atenolol
61. Nimustine
62. Prithyldone

63. Isosorbidemononitrate

64. Any new drug for which the company conducted clinical trials and obtained Drug Controller's approval.

65. Polio Vaccine

66. Measles Vaccine.

Non-reduction of prices of formulations

3777. SHRI SANTOSH KUMAR SAHU :
SHRI RAJNI RANJAN SAHU :
CHOWDHARY RAM SEWAK :

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1324 given in Rajya Sabha on 5th December, 1991 and state :

(a) what are the names of other drugs besides Analgin where formulation prices based thereon were not reduced on the ground that BICP had pointed out certain anomalies and sought clarifications ;

(b) what were the anomalies pointed out by the BICP and clarifications needed by the BICP in respect of each of the bulk drugs so involved;

(c) whether in most of these cases formulations prices were not reduced if so, in how many cases they remain to be worked out till date ; and

(d) by when the prices would be reduced based on the reduced prices of bulk drugs?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) Names of such bulk drugs are as under :

1. Phenytoin Sodium
2. Metronidazole
3. Metronidazole Benzoate
4. Ibuprofen
5. Amoxycillin Trihydate
6. Sulphamethoxzazole
7. Methyldopa
8. Isoxuprine
9. Sulphamoxole.

(b) Anomalies pointed out and clarifications sought were basically regarding the approach and methodology for reducing the prices.

(c) and (d) While answering Rajya Sabha Unstarred Question No. 673 dated 28-11-1991, it was stated that before Government could notify the prices of ceiling packs of connected formulations on reduced prices of bulk drugs, there was change in exchange rate of rupee against major foreign currencies. As a result, prices of 9 out of 11 bulk drugs (including Analgin) had been revised upwards. In 4 cases, the revised prices were even more than the pre-revised price. The exercise to notify the prices of ceiling packs of formulations where the bulk drug prices were still less than the pre-reduced price has since been completed.

Prices of Medicines

3778. SHRI RAJNI RANJAN SAHU:
SHRIMATI BIJOYA CHAKRAVARTY:
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1325 given in the Rajya Sabha on 5th December, 1991 and state:

(a) what are the names of the medicines where prices of bulk drugs and formulations have come down on account of competition;

(b) whether it is a fact that prices have steeply risen in all such cases after decontrol ; and

(c) if so, the details of such cases?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) to (c) Though no study has been conducted to establish, or otherwise such a relationship in pharmaceutical sector, it is generally accepted principle that market competition with adequate supply results in reduction in prices.

Reduction in the prices of formulations

3779. CHOWDHARY RAM SEWAK :
SHRI SANTOSH KUMAR SAHU :

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1324 given in the Rajya Sabha on 5th December, 1991 and state:

(a) whether Government have promised to reduce the prices of formulations